Nebulised hypertonic saline for cystic fibrosis (Q24241042)

https://api.crossref.org/works/10.1002%2F14651858.CD001506.PUB3

7 January 2021

Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001506.PUB3

7 January 2021

Consensus conference: practical applications of Pulmozyme. September 22, 1993.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001506.PUB3

7 January 2021

Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001506.PUB3

7 January 2021

Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001506.PUB3

7 January 2021

Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001506.PUB3

7 January 2021

Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001506.PUB3

7 January 2021

A cost-effectiveness analysis of rhDNase in children with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001506.PUB3

7 January 2021

The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001506.PUB3

7 January 2021

Mucus clearance and lung function in cystic fibrosis with hypertonic saline

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001506.PUB3

7 January 2021

A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001506.PUB3

7 January 2021

Meta-analyses involving cross-over trials: methodological issues

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001506.PUB3

7 January 2021

Inhaled hypertonic saline increases sputum expectoration in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001506.PUB3

7 January 2021

Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001506.PUB3

7 January 2021

Controlled trial of intermittent aerosol therapy with sodium 2-mercaptoethane sulphonate in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001506.PUB3

7 January 2021

Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001506.PUB3

7 January 2021

Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001506.PUB3

7 January 2021

https://api.crossref.org/works/10.1002%2F14651858.CD001506.PUB3

1 reference

7 January 2021

Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001506.PUB3

7 January 2021

Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001506.PUB3

7 January 2021

10.1002/14651858.CD001506.PUB3

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1136166

OpenCitations bibliographic resource ID

1136166

1 reference